蓝瑟斯
估值 各估值倍数与自身5年区间的对比
同业对比 Drug Manufacturers - Specialty & Generic
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 蓝瑟斯 (LNTH) | 6.51B | 23.85 | 4.96 | 0.00% |
| Takeda Pharmaceutical (TAK) | 62.84B | -59.43 | 1.31 | 3.04% |
| Teva Pharmaceutical Industries (TEVA) | 48.40B | 69.17 | 6.24 | 0.00% |
| Haleon (HLN) | 44.55B | 21.06 | 2.05 | 1.88% |
| Zoetis (ZTS) | 32.80B | 12.95 | 10.42 | 2.60% |
| United Therapeutics (UTHR) | 22.87B | 19.10 | 3.57 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价高于晨星合理价值估算15.2%。
合理价值
Lantheus Holdings Inc receives a 2-star quantitative star rating, reflecting our opinion that this share class is a somewhat unattractive choice, and investors should look elsewhere for more fruitful opportunities. The stock currently trades at a 19% premium over our quantitative fair value estimate of $84.51 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.
The firm's valuation metrics decrease our estimated fair value. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 20.1% falls in the bottom 20% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.
On a different note, the firm's profitability is reassuring. Highly profitable companies are often more resilient in recessions and are likely to generate stronger future cash flows for shareholders. The firm's earnings yield of 6.0%, for example, sits in the top 40% globally. This suggests that it is generating substantial earnings relative to its share price, which, despite our unfavorable price/fair value ratio, is a positive attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.
经济护城河
The company's narrow quantitative moat rating indicates it could outearn its cost of capital and maintain robust margins for 10 years or longer. Its moat is bolstered by its strong financial health, which indicates low near-term bankruptcy risk.
作者:Quantitative Equity Report
报价时间 2026-10-16 20:02:30 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
蓝瑟斯 讨论区 0 条评论